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In brief 
 Discusses the highly variable way in which mouth cancer can present clinically and as 
such any persistent mucosal abnormality should be viewed with suspicion. 
 Emphasises that the detection of mouth cancer whilst the tumour is less than 2cm in 
diameter is the single most important factor that can improve patient outcome. 
 Provides information on diagnostic aids for mouth cancer and potentially malignant 
mucosal disorders. 
 Outlines the guidance on the appropriate referral of urgent suspected cancer. 
 
Abstract 
Mouth cancer can present as a variety of abnormalities and visible changes affecting the oral 
mucosa, including ulceration, swelling and areas of erythema.  The five-year survival from 
mouth cancer is poor at approximately 50%.  Detection of the cancer whilst less than 2cm in 
diameter with no metastasis greatly improves the outcome for the patient.  Although many 
cancers in the mouth develop from what was previously an apparently normal mucosa, some 
arise in pre-existing conditions which are therefore regarded as potentially malignant.  
Regular assessment of the soft tissues within the mouth and the neck for the presence of 
abnormalities is an essential component of primary dental care.  Any persistent and 
unexplained abnormality requires referral for definitive diagnosis and specialist management. 
 Introduction  
Certain conditions that affect the oral mucosa have characteristic clinical signs and symptoms 
that allow diagnosis on the basis of clinical presentation alone without the need for special 
investigations.  Examples of these would be the distinctive history and appearance of minor 
recurrent aphthous stomatitis and geographic tongue.  However, squamous cell carcinoma 
(mouth cancer) contrasts with this markedly in that it can present with a range of mucosal 
changes and symptoms.  On this basis any persistent solitary mucosal abnormality should be 
regarded as potentially sinister until proven otherwise. 
 
One of the main reasons that that mouth cancer is given such high importance in dentistry and 
has been recommended as a topic for Continuing Professional Development is the poor 5-
year survival, which overall is approximately 55%.1  The single most important factor that 
can improve 5- year survival is detection of the tumour whist small, specifically 2cm or less 
in diameter with no regional node involvement or distant metastases (Stage I).  Patients with 
a tumour detected at Stage I are associated with an 85% five year survival compared to those 
with Stage IV (greater than 4 cm in diameter with regional node involvement and possible 
distant metastasis) for whom the five year survival is only 10%. 1,2.  The importance of 
detection whilst small was also highlighted in a recent retrospective study of survival after 
aggressive surgery which revealed that a patient with a tumour that is detected with a 
maximum diameter 2cm (Tumour stage T1) had a mean post-treatment survival of 24.48 
years (95% CI 22.45-26.50) whilst a patient with a tumour greater than 4cm (Tumour stage 
T4) had a mean survival of only 13.03 years (95% CI 11.56 – 14.49).3  These figures for 
survival are longer than those reported in studies and in part it must be appreciated that the 
research involved only one centre.  In reality the five year survival from advanced cancer is 
usually much shorter than 13 years. 
 
It is important to appreciate that velocity of cancer growth in the mouth is not uniform.  Some 
tumours may slowly increase in size over many months whilst others enlarge rapidly over a 
few weeks.  On this basis the concept of “early” diagnosis is slightly misleading since it is not 
actually the time that the cancer has been present that is most important but the size and 
presence of regional metastasis when the tumour is first detected that is key to an improved 
chance of survival for the patient. 
 
It is useful to recognise that oral squamous cell carcinoma essentially represents epithelial 
cell replication within the lining of the mouth that is “out of control” and as such is a surface 
event which should be visible on clinical examination.  This feature contrasts with some other 
tumours that are not “visible”, such as ovarian cancer or pancreatic cancer.  It is not 
unreasonable to expect a dental care professional to be able to detect a surface mucosal 
abnormality that is 2cm in diameter since this size is approximately that of a human finger 
nail. 
 
Clinical presentation 
The classical appearance of mouth cancer is a solitary deep ulcer with rolled margins on the 
lateral margin of the tongue (Fig. 1).  Palpation of the margin of the ulcer will reveal firm, 
often described as indurated, tissues.  Unfortunately however other than induration, mouth 
cancer has no pathognomonic presenting feature and involves a spectrum of mucosal changes 
in addition to ulceration including swelling (Fig. 2), erythema (Fig. 3) or a speckled red/white 
patch (Fig 4)4. 
 Examination of the patient 
A number of educational videos showing methods of clinical examination of the mouth and 
neck are freely available on the internet via providers such as YouTube or Google video.  
However, the three minute Oral Cancer Recognition Toolkit video developed by Cancer 
Research UK and the British Dental Association is particularly useful for dental 
professionals.5 
 
Extra-oral examination 
The soft tissues of the neck should be palpated on both sides using the tips of the fingers to 
detect any abnormal tissue swelling or enlargement of the lymph nodes.  The patient’s neck 
should be flexed and the examination start in the submental region moving back to the 
submandibular region, then down the jugular chain to the supra-clavicular fossa. 
 
Intra-oral examination 
There is no correct order for examining the oral soft tissues as long as that at the completion 
of the examination the entire mouth and the oropharynx, including the tonsils has been 
assessed.  Good lighting is obviously essential.  Any mucosal abnormality noted should be 
palpated to determine consistency of the soft tissue (Fig. 5).  As a general rule, induration 
reflects the presence of a benign or malignant neoplasm whilst softness to palpation 
represents a non-neoplastic inflammatory condition.  In addition, mouth cancer is often 
painless until well advanced whilst inflammatory conditions are usually painful from the 
outset. 
 
Mucosal Biopsy 
A scalpel biopsy is the gold standard investigation for the diagnosis of any mucosal 
abnormality.  The biopsy may be excisional or incisional depending on the size of the 
abnormality detected.  Small areas of mucosal change can be removed with a surrounding 
margin of clinically normal mucosa.  There is divided opinion on the complete removal of a 
small mucosal abnormality that is found to be cancer since it may subsequently cause 
problems in identifying the primary site.  However, the vast majority of small localised 
mucosa lesions are not squamous cell carcinoma and in the cases where they are modern 
imaging techniques and clinical examination will indicate the diagnostic surgical site.  In the 
case of larger areas of change, a clinical decision has to be made as to what tissue to remove.  
As a rule the most suspicious looking area of mucosa should be included in the biopsy 
material.  The tissue specimen should therefore include any aspects of ulceration, induration, 
erosion and erythema along with some apparently normal adjacent mucosa. 
 
Following the placement of local anaesthesia, an incisional mucosal biopsy should involve 
the taking of an elipse of tissue from the affected site.  It is helpful to firstly place a suture in 
the tissue to be removed.6  This is preferable to the use of toothed-tissue tweezers since these 
may become dislodged and frequent re-application can cause crush damage to the biopsy 
material.  A number 15 blade with a rounded tip is the scalpel of choice for the majority 
forms of oral surgery.  The lower incision is made first to prevent bleeding potentially 
obscuring the site of the upper incision (Fig. 6).  The tissue can then be removed as a sheet of 
mucosa.  Closure of the surgical defect can be made with simple interrupted sutures using 
either a resorbable or non resorbable material (Fig. 7).  A wide range of suture materials are 
available and their use depends of the type of surgery being undertaken.  Although black silk, 
a non-resorbable material, has historically been used for intra-oral soft tissue closure, 
resorbable polyglactin 910 (a copolymer of 90% glycolide and 10% L-lactide), is now the 
preferred material.  Sutures are available on a variety of needles which differ in cross section, 
size and length.  A 19mm curved reverse cutting needle, which is triangular in cross section, 
is the needle of choice for closure of the oral mucosa. 
 
The biopsy tissue removed can be supported on filter paper before placement in a pre-labelled 
specimen pot containing 10% neutral buffered formalin to minimise the impact of shrinkage 
and distortion during fixation (Fig. 8).  This step is important since curling up of the tissue 
can cause cross sectioning that may be mistaken for epithelial invasion in tissue sections 
when examined microscopically in two dimensions. 
 
Punch biopsy 
Punch biopsy, which removes a cylindrical specimen of tissue of between 0.4-0.8 mm in 
diameter, has been promoted as a simple and quick method of sampling the oral mucosa.7  
However, since the amount of tissue removed is relatively small there is potential to not 
obtain sufficient material when assessing the epithelium for the presence of dysplasia or 
invasion.  On this basis some oral & maxillofacial pathologists have expressed a preference 
for a scalpel biopsy rather than punch biopsy (personal communication). 
 
Potentially malignant conditions 
A primary mouth cancer can either arise in what was previously clinically normal tissue or 
develop within a pre-existing mucosal abnormally.  Such pre-existing conditions that are 
associated with an increased incidence of undergoing malignant transformation are referred 
to as being oral potentially malignant disorders (OPMDs) (Table). 
 
Leukoplakia 
The most frequently recognised OPMD is leukoplakia (Fig. 9), which was first defined by the 
WHO in 1978 as “a white patch or plaque that cannot be characterised clinically or 
pathologically as any other disease”.8  The term has subsequently been refined following 
various international workshops and is now used to describe “white plaques of questionable 
risk having excluded (other) known diseases and disorders that carry no increased risk for 
cancer”.9  It is essential to remember that leukoplakia is a clinical term and not a diagnosis.  
A biopsy is required to exclude know mucosal disorders.  Although often associated with the 
presence of epithelial dysplasia leukoplakia itself has no specific histopathological features.  
The reported malignant transformation rate for oral leukoplakia has ranged from low levels of 
0.13% in India10  and 2.6 % in the UK11 to high levels of 17.5% in USA.12  These findings are 
undoubtedly influenced by the geographical site, population studied, number of patients and 
length of follow-up observation period.  The global malignant transformation rate of 
leukoplakia is generally accepted to be 1.36% per year.13 
 
There is a rare form of leukoplakia, termed proliferative verrucous carcinoma (PVL), which 
has a reported transformation rate as high as 70%.14  The presentation of PVL is characterised 
by an initial white patch that develops into multiple areas of exophytic / wart-like changes 
within the mucosa.  The aetiology of PVL is unknown and treatment difficult due to 
progressive recurrence following surgical removal. 
 
Erythroplakia 
Oral erythroplakia (Fig. 10) is defined as “a fiery red patch that cannot be characterised 
clinically or pathologically as any other definable lesion”.15  Erythroplakia, in a similar way 
to leukoplakia has no specific histopatholigical features.  The term is used clinically to record 
the presence of an erythematous mucosal abnormality that does not have  a clinical 
appearance characteristic of known red patches, such as denture associated candidosis or 
median rhomboid glossitis.  Oral erythroplakia has the highest transformation rate of all of 
the OPMDs, being reported as between 14% -50%.16  Erythroleukoplakia is an alternative 
clinical term that can be used when the mucosa has a speckled red and white appearance.  
Importantly erythroleukoplakia is associated with a high risk of malignant change. 
 
Lichen planus 
The aetiology of oral lichen planus (OLP) is unknown but does involve immune system since 
a primary histopathological feature is a sub-epithelial band of T-lymphocytes, indicating a 
cell mediated reaction.  OLP is one of the most frequently occurring mucosal conditions in 
the population, with a reported prevalence of between 0.5-2.2%.17  Different types of OLP 
have been described, including reticular, atrophic, erosive, plaque-like and bullous, based on 
the appearance of the mucosa.  However, actual typing in an individual patient is often 
difficult since different types may be present simultaneously and also change during the 
course of disease over months.  Overall, the most characteristic feature is the presence of 
bilateral white striations in the buccal mucosa (Fig. 11).  The reported malignant 
transformation for OLP worldwide has varied between 0.4-6.4% depending on population 
studied and length of follow-up period.  Two historical UK based studies revealed yearly 
transformation rates of 0.07% and 0.27%.18,19  A recent systematic review revealed an 
increased transformation risk in females with red clinical forms on the tongue.20 
 
Submucous fibrosis 
Submucous fibrosis is a chronic disorder of the upper alimentary tract, which presents most 
obviously within the mouth as vertical fibrous bands in the buccal mucosa that limit mouth 
opening.  The patient will also complain of an overall burning sensation within the mouth, 
including the buccal mucosa may appear white or erythematous (Fig. 12).  Oral submucous 
fibrosis (OSF) has a strong association with the social habit of chewing areca (betel) nut, 
which is popular in populations living in and originating from the Indian subcontinent and 
surrounding countries.  Alkaloids within the nut stimulate fibroblast proliferation.  The 
malignant transformation rate from a long term follow up study of OSF in an Indian 
population was reported as 7.6%.21 
 
Palatal keratosis in reverse smokers 
Reverse smoking, in which the lit end of a cigar or cigarette is placed in the mouth, is popular 
in the rural populations of the Amazon, New Guinea and Indian subcontinent.  The physical 
irritation from heat and tobacco smoke induces hyper-keratinization and erythamatous 
changes within palatal mucosa.  A high incidence of cancer in the hard palate, which is a 
relatively rare site in non-reverse smokers, has been associated with this habit.22 
 
Other OPMDs 
Actinic keratosis is associated with exposure to ultraviolet light and characteristically affects 
the vermilion lower lip presenting as palpable white plaques.  Regular review is required and 
the development of palpable induration would indicate the need for biopsy to exclude 
transformation into either a squamous cell carcinoma or basal cell carcinoma (Fig. 13).  The 
actual transformation rate of actinic keratosis is unknown.  Discoid lupus erythematous, 
which can on occasions produce oral signs that resemble oral lichen planus or erythroplakia, 
has been reported to transform into squamous cell carcinoma.  Dyskeratosis congenita, an 
example of inherited OMPD, is a bone marrow disorder that is associated with oral white 
patches (Fig. 14) which transform into mouth cancer and cause death in young adulthood.23 
 
Although not included in the WHO list of OPMDs, chronic hyperplastic candidosis (CHC) is 
recognised as having the potential to undergo malignant transformation.24  CHC 
characteristically presents as bilateral adherent white patches in the buccal commissure 
regions of the mouth (Fig. 15) or dorsum of tongue.  This type of oral candidosis is seen 
almost exclusively in smokers.  Although the provision of systemic antifungal therapy will 
produce a dramatic clinical improvement, CHC will recur if the patient does not stop the 
tobacco habit.  All patients with CHC should be provided with smoking cessation advice. 
 
Detection aids 
As mentioned above, mouth cancer has a wide spectrum of clinical presentation with no 
pathognomonic feature.  It has been demonstrated that dentists, dental hygienists and dental 
therapists are able to confidently recognise mucosal abnormalities and have relatively high 
accuracy for the clinical detection of mouth cancer or OMPD.25  However, it is generally 
accepted that even whilst the most experienced clinician may have strong suspicion of the 
presence of squamous cell carcinoma, there can never be 100% certainty until the diagnosis is 
confirmed on the basis of histopathological findings following gold standard mucosal biopsy.  
Occasionally a highly suspicious clinical area of mucosa change is found to be an essentially 
benign abnormality and conversely a benign looking mucosal abnormality can be found to 
contain a carcinoma.  The lack of specific clinical signs for mouth cancer probably in part 
accounts for the delay in a patient seeking an opinion of dentist or doctor in primary care and 
hence the high percentage of patients who are not diagnosed till the tumour has advanced to 
Stage III or Stage IV.1 
 
A range of adjunctive clinical aids have been and are continuing to be developed 
commercially to increase the detection of potential mouth cancer at the chair side.26  The 
technology involved includes the use of nuclear dyes, tissue reflectance light visualization 
and fluorescence imaging, all of which aim to increase the clinician’s ability to detect an area 
of mucosal abnormality that may represent cancer or OMPDs.  The primary aim of such 
diagnostic adjuncts is to increase the proportion of mouth cancers that are detected in primary 
care whilst at Stage I or Stage II.  The promotion of these diagnostic aids not only emphasises 
the importance within the dental profession to thoroughly assess the oral mucosa but when 
used in the clinic also raises awareness of the potential of mouth cancer in patients.  
However, the subjective interpretation of the tests coupled with relatively good sensitivity but 
poor specificity, makes their use problematic.  There is limited evidence to support the use of 
light based techniques in primary care.27,28.  At the present time further research is required to 
develop the technology to achieve a tool that could be used as an effective screen for mouth 
cancer within the general population.  It is not possible to present details of all the available 
diagnostic adjuncts here (for reviews, see Macey et al.29  and Lingen et al.30).  Some of the 
more widely known systems are described below. 
 
Vital tissue staining 
The use of vital tissue staining in cancer detection is based on the assumption that a nuclear 
dye will be taken up in the epithelial cells where there is a high density of nuclear material, 
such as in malignancy, and therefore have a different appearance to normal mucosa.  This 
methodology was originally used for cervical screening in women.  Toluidine blue (tolonium 
chloride) is a metachromatic dye has been used widely in this context.  Retention of the dye, 
seen as dark blue, following application and de-staining with acetic acid is considered 
positive (Fig. 16).  However, it is not cancer specific and false positives due to uptake by 
benign inflammatory and ulcerative of the oral mucosa are frequent.   Equally, failure of the 
dye to penetrate keratinised mucosa can lead to false negatives.  A Cochrane review of the 
use of the toluidine blue test for detection of oral carcinoma or OPMDs in 14 studies reported 
an overall sensitivity of 0.84 and specificity of 0.70 for both conditions.29 
 
Tissue reflectance light visualization 
The use of tissue reflectance or chemiluminescence to detect cancer is based on the theory 
that the increased nuclear to cytoplasmic ratio of malignant epithelial cells results in 
increased light reflectance when compared to normal mucosa.  ViziLite Plus ( Panadent, 
Orpington, UK) and MicroLux DL (Panadent, Orpington, UK) are two cancer detection 
systems that employ this approach.  The systems differ in their light sources with ViziLite 
Plus using a disposable stick (490-510 nm wavelenghts) and MicroLux DL using a battery 
operated device (410 – 710 nm).  Abnormal mucosa appears “aceto-white” when compared to 
normal tissues which are light blue.  Both systems have been found to brighten areas of 
leukoplakia, which had already been detected using conventional examination.  
Unfortunately, due to the lack of surgical biopsy information in the studies evaluating these 
two systems it is not possible to determine sensitivity and specificity figures. 
 
Fluorescence imaging 
It has been discovered that cancer cells have different autofluorescence emission patterns 
when compared to normal tissues.  The Visually Enhanced Lesion Scope (VELscope, LED 
Dental Inc, White Rock, British Columbia, Canada) is a hand held device that shines high-
intensity blue excitation light (400-460 nm wavelengths) onto the oral mucosa.  Normal 
tissues fluoresce green whilst malignant cells appear relatively dark.  Unfortunately, some 
normal tissue or benign conditions may also remain dark.  A Cochrane review of 12 studies 
of the use of VELscope reported an overall sensitivity of 0.91 and specificity of 0.58 for oral 
carcinoma or OPMDs.29 
 Brush cytology 
Exfoliative cytology has been investigated as a possible mouth cancer detection system.  
OralCDx (OralCDx Laboratories, Inc) is an example of this technology that uses a special 
designed brush to collect cells from an identified mucosal abnormality within the mouth.  The 
sample is then sent for computerised analysis for the presence of abnormal cells and reported 
as negative, atypical or positive.  All atypical and positive results require a tissue biopsy.  
OralCDx has been found to have a sensitivity of 0.92 and specificity of 0.94 to detect 
dysplasia or squamous cell carcinoma.31  More recently cytological methods have been 
combined with molecular markers in an attempt to improve their prognostic value. 
 
Salivary diagnostics 
Molecular biology has enabled the ability to detect biomarkers (peptides, proteins, DNA, 
mRNAs, and miRNAs) in saliva and as such provide a non-invasive diagnostic test and 
screening tool for human disease.  The potential to use saliva to detect the presence of cancer 
has been researched in relation to tumours of the ovary, breast, pancreas and lung.  In 
addition, a number of studies have been undertaken to look at biomarkers for oral squamous 
cell carcinoma.32 - 35.  At the present time further work is required to identify specific 
biomarkers within saliva that can be reliably used to detect different forms of human cancer 
and other forms of disease.  Salivary diagnostic technology has huge potential for the future 
and could become a routine aspect of dental primary care. 
 
Referral 
As previously described, the outcome of mouth cancer is significantly improved if the tumour 
is detected and treated when it is less than 2cm in diameter with no local metastasis.  On this 
basis any suspected cancer patient should be referred for specialist assessment rapidly.  
Terminology used in this situation is urgent suspected cancer (USC) with an expectation, in 
the UK , that a patient referred a USC will be seen within 14 days (2 week wait, 2WW) or 10 
working days(10 day rule) (1).  The 2WW system for cancer, including head and neck cancer, 
was introduced in the UK in 2000 and there is little doubt that it has been valued by patients 
since it speeds up the overall management.  An audit of 2WW rule in the Oral and 
Maxillofacial Surgery department at the Newcastle General Hospital and then subsequently 
in the Oral Surgery and Oral Medicine departments at Newcastle Dental Hospital revealed  
positive head and neck cancer detection rates of 11% and 7% respectively in the cohorts of 
patients examined.36  A similar study at the Oral Medicine department in King’s College, 
London, reported that 8% of urgent referrals were found to have oral cancer.37  Both audits 
concluded that further education of referring practitioners and refinement of the referral 
guidelines were required to ensure a more efficient service. 
 
A systematic review of the impact of the 2WW rule for head and neck cancer between 2000-
2014 concluded that the conversion rate (proportion of 2WW referrals who were diagnosed 
as having cancer) was falling, the detection rate (proportion of diagnosed cancers referred 
under 2WW rule) was rising due to increased number of referrals.  In addition the impact of 
the 2WW rule on outcome, particularly survival, was not clear.38 
 
Methods of referral from primary care to specialist secondary care vary widely.  Historically 
referrals have been made in the form of a written letter with inevitable risk of delay within a 
postal system.  This has in part been overcome by the use of a fax machines or a secure NHS 
email address.  Personal email accounts must not be used due to the high risk of breach of 
patient confidentiality.  However, free written communication via any of these methods may 
be problematic in that the clinical information provided by the primary care practitioner may 
be insufficient to enable the receiving specialist to identify the need for a 2WW appointment.  
The inclusion of a question on a preformed referral forms “Do you think that this patient may 
have a cancer? or a “Yes / No” tick-box for USC is helpful but again not foolproof.  Details 
of risk factors for the patient, in particular any tobacco, betel nut or alcohol habits, are 
important to include. 
 
Electronic record management and referral systems within managed clinical networks 
(MCNs) are being introduced and these have a range of advantages, including an assurance of 
rapid and safe delivery of the referral request.  In addition, some electronic systems ensure 
that all relevant information is provided by the referring practitioner since the referral will not 
be accepted until this is completed online.  Individual practitioners must be aware of their 
local referral system. 
 
In the UK, the National Institute for Health and Clinical Excellence (NICE)39 and Healthcare 
Improvement Scotland (HIS)40 have published referral guidelines to help clinicians decide 
which patients should be refereed as USC.  These guidelines focus on the presenting clinical 
symptoms and recommend the need for a USC referral for any individual with; 
 Unexplained ulceration in the oral cavity lasting more than three weeks 
 A persistent and unexplained lump in the neck. 
 A lump on the lip or in the oral cavity consistent with oral cancer 
 A red or red and white patch in the oral cavity consistent erythroplakia or 
erythroleukoplakia 
There has been discussion in relation to the recommendation that a doctor should refer a 
patient to a dentist for assessment within two weeks if the doctor thinks that there is a lump 
on the lip or in the oral cavity consistent with oral cancer or a red or red and white patch in 
the oral cavity consistent erythroplakia or erythroleukoplakia.  Concern has been expressed 
that due to the lack of a clear pathway between the doctor and the dentist that this advice 
exposes the patient to unnecessary delay in diagnosis.41,42  
 
Communication with the patient 
If a soft tissue examination reveals an abnormality and it is felt that a referral is indicated 
then what should the patient be told?  It is probably best to inform the patient that changes in 
the mouth are seen frequently and the vast majority are innocent but it is best to get it double 
checked by a specialist.  Other information given to the patient and career could include;. 
Where there are being referred, How long they may have to wait, Who will see them, and 
What types of test may be done.43  This communication has to be done sensitively and 
obviously the amount of information given decided on an individual patient basis. 
 
Interestingly, it has been reported that some dentists have a reluctance to discuss mouth 
cancer with their patient due to a lack of confidence to answer patient’s questions (44).  There 
would appear to be a need for specific training and guidance for the dental team on how to 
raise the issue of mouth cancer during routine examination and also how to communicate any 
issues without causing unnecessary anxiety.  This aspect of mouth cancer could be a subject 
for future undergraduate and postgraduate education. 
 
Conclusion 
Mouth cancer can present in a variety of changes within the orofacial tissues.  Regular and 
thorough examination of the soft tissues is an essential aspect of dental primary care.  If any 
abnormality detected is thought to possibly represent cancer, then the patient needs to be 
referred appropriately for a specialist evaluation.  Detection of mouth cancer whilst small is 
key to an improved outcome for the patient.  All dental professional should be feel 
comfortable about discussing mouth cancer with their patients. 
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 Legends to Figures 
Fig. 1.  SCC as a solitary deep ulcer with rolled margins with no obvious cause. 
Fig. 2.  SCC as mucosal swelling with speckled surface in left buccal mucosa  
Fig. 3.  SCC as an erythematous mucosal patch in left oropharynx. 
Fig. 4.  SCC as a predominantly white mucosal patch on the left lateral margin of the tongue.  
Fig. 5.  Bimanual palpation of soft tissues in the floor of mouth. 
Fig. 6.  Lower incision during an incisional biopsy of white patch in the floor of the mouth. 
Fig. 7.  Defect following removal of biopsy material (A).  Closure of biopsy defect using 
simple interrupted silk sutures (B). 
Fig. 8.  Biopsy tissue placed on filter paper prior to placement into pathology specimen pot. 
Fig. 9.  Leukoplakia on the left lateral margin of the tongue. 
Fig. 10.  Erythroplakia in the right side of the floor of mouth. 
Fig. 11.  Lichen planus presenting as bilateral and symmetrical white striations in the buccal 
mucosa. 
Fig. 12.  Submucous fibrosis presenting as bilateral white patches in the buccal mucosa.   
Fig. 13.  Squamous cell carcinoma arising in pre-existing actinic keratosis. 
Fig. 14.  White patch on dorsal surface of the tongue in dyskeratosis congenital (Courtesy of 
Professor Graham Ogden). 
Fig. 15.  Chronic hyperplastic candidosis presenting as bilateral white patches in the buccal 
mucosa. 
Fig. 16.  Toludine blue stain retained on palatal mucosal abnormality. 
 
  
Table  Oral potentially malignant disorders of the oral mucosa (9) 
Leukoplakia 
Erythroplakia 
Palatal lesions in reverse smokers 
Oral submucous fibrosis 
Actinic keratosis 
Lichen planus 
Discoid lupus erythematosus 
Hereditary disorders with increased risk 
